Predictive value of positron emission tomography/computed tomography to assess early treatment response to dual human epidermal growth factor receptor 2 (HER2) blockade without chemotherapy for HER2-positive metastatic breast cancer: Are we ready to embrace this "early metabolic look" strategy? Editorial Article uri icon

Overview

MeSH Major

  • Antineoplastic Combined Chemotherapy Protocols
  • Breast Neoplasms
  • Fluorodeoxyglucose F18

publication date

  • August 20, 2015

Research

keywords

  • Editorial

Identity

Digital Object Identifier (DOI)

  • 10.1200/JCO.2015.62.3082

PubMed ID

  • 26195716

Additional Document Info

start page

  • 2591

end page

  • 3

volume

  • 33

number

  • 24